Tuesday's Health Winners & Losers

Earnings regenerated a few health stocks on Tuesday, while others were anemic on various news.

Regeneration Technologies(RTIX Quote) rose Tuesday after announcing earnings. Revenue was $22.9 million, compared with $18.3 million for the year-ago period. The company reported net income of $195,000, or 1 cent a share, compared with a loss of $1.6 million or 5 cents a share in the 2006 quarter. Earnings were in line with the expectations of analysts surveyed by Thomson Financial. Regeneration Technologies gained 85 cents, or 8.6%, to $10.72.

Similarly, Auxilium Pharmaceuticals(AUXL Quote) rose after reporting earnings. The company reported revenue of $23.3 million, vs. $16.5 million in the 2006 quarter. Auxilium lost $10 million, or 27 cents a share, in the quarter, compared with $11.7 million, or 40 cents a share, a year ago. Analysts, according to Thomson Financial, were looking for a loss of 30 cents a share. The stock added $1.36, or 8.4%, to $17.47.

Biopharmaceutical company ImmunoGen(IMGN Quote) got a boost Tuesday after announcing that Genentech(DNA Quote) started a phase II clinical testing of trastuzumab-DMI (a combination of a Genentech antibody with a cell-killing agent from ImmunoGen). The deal triggers a $5 million milestone payment to ImmunoGen. Genentech is developing the trastuzumab-DMI for a possible breast cancer treatment.

ImmunoGen gained 28 cents, or 6.2%, to $4.77, while Genentech was down $1.83, or 2.4%, to $74.42.